These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9919340)

  • 21. Chemotherapy in the treatment of advanced pelvic malignant disease with special reference to ovarian cancer.
    Limburg H; Heckmann U
    J Obstet Gynaecol Br Commonw; 1968 Dec; 75(12):1246-55. PubMed ID: 5702360
    [No Abstract]   [Full Text] [Related]  

  • 22. The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer.
    Kim YM; Lee SW; Kim DY; Kim JH; Nam JH; Kim YT
    J Chemother; 2010 Jun; 22(3):197-200. PubMed ID: 20566426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Not Available].
    Kurtz JE; D'Hondt V; Lécuru F; Lhommé C
    Bull Cancer; 2017 May; 104 Suppl 1():S39-S42. PubMed ID: 28625314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical applications of the camptothecins.
    Takimoto CH; Wright J; Arbuck SG
    Biochim Biophys Acta; 1998 Oct; 1400(1-3):107-19. PubMed ID: 9748525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug therapy for gynaecological cancer in older women.
    van Rijswijk RE; Vermorken JB
    Drugs Aging; 2000 Jul; 17(1):13-32. PubMed ID: 10933513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer.
    Bryant CS; Kumar S; Spannuth W; Shah JP; Munkarah AR; Deppe G; Alvarez RD; Morris RT
    Arch Gynecol Obstet; 2011 Feb; 283(2):361-7. PubMed ID: 20383771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New drug therapy for squamous carcinoma of the head and neck.
    Murphy BA
    Curr Opin Oncol; 1996 May; 8(3):221-6. PubMed ID: 8794150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The development of camptothecin analogs in childhood cancers.
    Bomgaars L; Berg SL; Blaney SM
    Oncologist; 2001; 6(6):506-16. PubMed ID: 11743213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cediranib aims for a comeback.
    Schmidt C
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25745013
    [No Abstract]   [Full Text] [Related]  

  • 31. Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor?
    Saltz L; Janik JE
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-26-S5-30. PubMed ID: 9122740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Irinotecan HCl, an anticancer topoisomerase I inhibitor, frequently induces ovarian failure in premenopausal and perimenopausal women.
    Tanaka T; Utsunomiya T; Utsunomiya H; Umesaki N
    Oncol Rep; 2008 May; 19(5):1123-33. PubMed ID: 18425367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
    Vergote I; Schilder RJ; Pippitt CH; Wong S; Gordon AN; Scudder S; Kridelka F; Dirix L; Leach JW; Ananda S; Nanayakkara N; Melara R; Bass MB; Litten J; Adewoye H; Wenham RM
    Gynecol Oncol; 2014 Oct; 135(1):25-33. PubMed ID: 25019569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues.
    Arun B; Frenkel EP
    Expert Opin Pharmacother; 2001 Mar; 2(3):491-505. PubMed ID: 11336601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines.
    Ling YH; Donato NJ; Perez-Soler R
    Cancer Chemother Pharmacol; 2001 Jun; 47(6):473-80. PubMed ID: 11459199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Radiotherapy-chemotherapy combinations in locally advanced cancers of the cervix].
    Vincent P; Chauvet B; Serin D; Brewer Y; Berger C; Reboul F
    Bull Cancer Radiother; 1996; 83(4):377-84. PubMed ID: 9081341
    [No Abstract]   [Full Text] [Related]  

  • 37. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
    Bookman MA
    Oncologist; 1999; 4(2):87-94. PubMed ID: 10337378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Irinotecan and radiation in combined-modality therapy for solid tumors.
    Choy H; MacRae R
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):22-8. PubMed ID: 11497228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical development of topoisomerase-interactive drugs.
    Muggia FM; Burris HA
    Adv Pharmacol; 1994; 29B():1-31. PubMed ID: 8996599
    [No Abstract]   [Full Text] [Related]  

  • 40. PARP inhibitors in cancer: moving beyond BRCA.
    Telli ML
    Lancet Oncol; 2011 Sep; 12(9):827-8. PubMed ID: 21862406
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.